Table 1.
Demographic and clinical information.
| OA | PD | OA vs. PD | ||||
|---|---|---|---|---|---|---|
| Non-Carrier | ε4 | Non-Carrier | ε4 | GBA | p-value | |
| n | 45 | 27 | 53 | 23 | 17 | N/A |
| Gender (F/M) | 25/20 | 15/12 | 14/39 | 9/14 | 3/14 | <0.001 |
| Age (yrs) | 69.9 (6.1) | 71.4 (7.3) | 68.7 (6.7) | 67.5 (8.9) | 62.5 (8.2) | =0.018 |
| MoCA Score | 26.7 (2.6) | 25.5 (3.6) | 25.9 (3.2) | 26.4 (2.3) | 26.1 (2.7) | =0.612 |
| Modified H&Y | 2.0 (1–4) | 2.0 (2–3) | 2.0 (1–3) | N/A | ||
| MDS-UPDRS III | 1.5 (2.0) | 2.7 (4.2) | 23.9 (12.5) | 25.2 (12.7) | 23.8 (13.9) | <0.001 |
| Disease Duration (yrs) | 8.2 (5.2) | 7.1 (4.1) | 7.4 (3.3) | N/A | ||
| LEDD | 694.4 (481.0) | 824.3 (526.4) | 771.8 (656.9) | N/A | ||
Mean (standard deviation). H&Y presented as median (min-max). The modified H&Y and MDS-UPDRS III scores were significantly difference between PD and OAs, but not within the PD or OA groups. Neither disease duration nor LEDD were significantly different among the PD genetic subgroups.